Related Experiment Video
Updated: Aug 10, 2026
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Optimizing the efficacy of epitope-directed DNA vaccination
Monika C Wolkers1, Mireille Toebes, Masaru Okabe
1Department of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Abstract:
An increasing number of clinical trials has been initiated to test the potential of prophylactic or curative vaccination with tumor Ag-encoding DNA vaccines. However, in the past years it has become apparent that for many Ags and in particular for tumor Ags the intracellular processing and presentation are suboptimal. To improve epitope-directed DNA vaccines we have developed a murine model system in which epitope-specific, DNA vaccine-induced T cell immunity can be followed by MHC tetramer technology directly ex vivo. We have used this well-defined model to dissect the parameters that are crucial for the induction of strong cytotoxic T cell immunity using two independent model Ags. These experiments have led to a set of five guidelines for the design of epitope-directed DNA vaccines, indicating that carboxyl-terminal fusion of the epitope to a carrier protein of foreign origin is the most favorable strategy. DNA vaccines that are based on these guidelines induce high-magnitude CD8(+) T cell responses in >95% of vaccinated animals. Moreover, T cell immunity induced by this type of optimized DNA vaccine provides long-term protection against otherwise lethal tumor challenges.
Insights
Optimizing DNA vaccines for cancer treatment is crucial. New guidelines for designing epitope-directed DNA vaccines improve T cell responses and provide long-term tumor protection.
Area of Science:
- Immunology
- Vaccinology
- Cancer Research
Background:
- Clinical trials for tumor antigen (Ag)-encoding DNA vaccines are increasing.
- Suboptimal intracellular processing and presentation of tumor Ags limit vaccine efficacy.
- Developing effective DNA vaccines requires strategies to enhance T cell immunity.
Purpose of the Study:
- To develop and validate a murine model for assessing epitope-specific T cell immunity induced by DNA vaccines.
- To identify critical parameters for inducing strong cytotoxic T cell (CTL) immunity against tumor Ags.
- To establish guidelines for designing improved epitope-directed DNA vaccines.
Main Methods:
- Utilized a murine model system to track epitope-specific T cell immunity.
- Employed MHC tetramer technology for direct ex vivo analysis of T cell responses.
- Evaluated two independent model Ags to dissect crucial parameters for CTL induction.
Main Results:
- Identified key parameters influencing T cell immunity, leading to five design guidelines for DNA vaccines.
- Carboxyl-terminal fusion of epitopes to foreign carrier proteins emerged as the most effective strategy.
- Optimized DNA vaccines induced high-magnitude CD8(+) T cell responses in over 95% of animals.
Conclusions:
- Developed evidence-based guidelines for designing potent epitope-directed DNA vaccines.
- Optimized DNA vaccines elicit robust and long-lasting T cell-mediated protection against tumor challenges.
- This approach significantly enhances the potential of DNA vaccines in cancer immunotherapy.
More Related Videos
08:13Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
Published on: January 20, 2019
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Vaccines